Pharmacology: noun phar·ma·col·o·gy ˌfär-mə-ˈkäl-ə-jē: the study of the interactions between drugs and biological systems toward the goal of developing novel therapies for human diseases.
The foundation of PBI’s comprehensive platform is our collective years of expertise in designing and conducting in vivo pharmacology & disease modeling. PBI’s scientific and research staff is experienced in study design, surgical techniques and in vivo functional evaluations. PBI’s animal care staff provides study support by ensuring appropriate and timely dosing, sampling and palliative care.
PBI’s in-house technologies provide for longitudinal, non-invasive functional measurements paired with high fidelity, invasive endpoint evaluations, producing data sets that span disease progression:
Non-invasive cardiac ultrasound and endpoint cardiac morphometric analysis;
- Non-invasive whole body plethysmography and endpoint FlexiVent direct pulmonary mechanics;
- Non-invasive tail cuff pressure-volume plethysmography and endpoint direct systemic or portal vein hemodynamics using Millar or fluid filled catheters;
- Serial GFR calculation from biomarker analytes and endpoint steady state renal glomerular filtration rate (GFR) and blood flow (RBF).
PBI studies address the medically complex nature of disease by studying the cardiac, diabetic, hepatic, renal and pulmonary therapeutic areas simultaneously or in isolation. Our preclinical models are well-characterized with respect to: disease progression; comparison to standards of care; and concurrent functional, histological and biochemical evaluation.